FinTechFunding

Invex Therapeutics: Receives UK approval to start phase III Presendin trial

Invex Therapeutics Receives UK approval to start phase III Presendin trial

  • Invex Therapeutics (IXC) gets the tick of approval to start its phase III Presendin trial in the UK, treating patients with idiopathic intracranial hypertension (IIH)
  • A total of 240 recently diagnosed IIH patients will either receive Presendin or a placebo once a week over 24 weeks in a double-blind trial
  • Patients with IIH suffer from raised intracranial pressure, causing disabling daily headaches and in some instances, a compressed optic nerve
  • The first patient is expected to be dosed after June 30
  • IXC ends the day 4.49 per cent in the green with shares trading at 46.5 cents
Previous article
FIS: Launches Guaranteed Payments for e-commerce merchants
Next article
What is license management?
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

WealthCom Secures $65M Funding Boost for Expansion

The investment aims to enhance service offerings and accelerate growth.Highlights: WealthCom raises $65 million in Series B funding.New...
FinTech

Financial Health Tools Could Unlock $5B in SME Lending

CFIT report highlights the potential of financial hygiene tools for small businesses.Highlights: CFIT report suggests financial health tools...
FinTech

Coinbase Strengthens UK Crypto Borrowing Options for Customers

Users can now borrow against their cryptocurrency holdings in the UK.Highlights: Coinbase now allows UK customers to borrow...
FinTech

Chase UK Appoints Monzo’s Malani as CEO, Strengthening Leadership Team

Former Monzo executive will lead Chase UK's growth strategy.Highlights: Chase UK appoints Monzo veteran Malani as CEO.This move...